Staple peptides represent a genuinely new frontier in medicine, said Professor Gregory Verdine, Harvard University, USA, when speaking this week at the 241st National Meeting of the American Chemical Society.
Prof. Verdine went on to say that these staple peptides are able to address targets previously considered "undruggable" by conventional therapeutics, such as small-molecule agents. In one advance, a staple peptide was able to target beta-catenin, an aberrant protein implicated in the progression of colon cancer and other types of cancer such as skin, brain and ovarian.
Studies are ongoing to establish the potential of these staple peptides as novel therapeutics.
Other articles related to the ACS meeting
Article Views: 1014